Answers are grounded in this paper and cite their sources.
Research investigates CysLT2 receptor roles in bronchoconstriction in asthma, suggesting new therapy avenues.
Background: Expression and functional roles of CysLT 2 receptors in asthmatic airways have been unclear. Objectives: Expression of both CysLT 1 and CysLT 2 receptors in the lung of asthma patients, and their functional roles in antigen-induced bronchial contraction were comparatively examined, and they were compared with those of non-asthma subjects. Methods: Expression of CysLT 1 and CysLT 2 receptors in the airway tissues isolated from asthma and non-asthma subjects were assessed by immunohistochemistry. As assessment of the functional roles, effects of a CysLT 2 receptor-specific antagonist, BayCysLT 2 RA, and a dual CysLT 1/2 receptor antagonist, ONO-6950 on antigen-induced bronchial contraction were evaluated in vitro. Results: Both CysLT 1 and CysLT 2 receptors were expressed on the smooth muscle and the epithelium of the bronchi, and alveolar leukocytes. Relative expression of CysLT 2 receptors to CysLT 1 receptors especially in the smooth muscle of the asthmatic lung showed a tendency to be higher than that in non-asthma subjects. CysLT 2 receptor-blockade hardly potentiated an inhibitory effect of a CysLT 1 -specific antagonist, montelukast, on the antigen-induced contraction of bronchi of non-asthma subjects. However, in the bronchus from one of 2 asthma patients, CysLT 2 receptor antagonism suppressed the contraction, and both CysLT 1 and CysLT 2 receptor blockade showed additive inhibitory effects on the anaphylactic contraction. Conclusions: CysLT 2 receptor activation by cysteinyl leukotrienes may play roles in a certain asthma patient, suggesting that CysLT 2 receptor antagonists and dual CysLT 1/2 receptor antagonists could be new therapeutic agents for asthma.
No takes yet. Share an insight, caveat, or question.
Nabe et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: